Releases
Ribo and Madrigal Advance siRNA Candidate for MASH Treatment
A strategic partnership between Suzhou Ribo Life Science and Madrigal Pharmaceuticals has reached its first major milestone, successfully nominating a lead candidate drug for metabolic dysfunction-associated steatohepatitis. The companies are now transitioning into IND-enabling studies to prepare for upcoming clinical trials.